WebJun 1, 2024 · In ZUMA-1, the pivotal, single-arm study of axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, the objective response rate (ORR) was … WebFred Locke, MD, Moffit Cancer Center, discusses the interim results from the ZUMA-I trial of Kte-C19. About Press Copyright Contact us Creators Advertise Developers Terms …
Did you know?
WebJan 4, 2024 · In the multicenter ZUMA-1 phase 1 study, we evaluated KTE-C19, an autologous CD3ζ/CD28-based chimeric antigen receptor (CAR) T cell therapy, in patients with refractory DLBCL. ... Moffitt Cancer Center, Tampa, FL 33612, USA. Electronic address: [email protected]. 2 Division of Cancer Medicine, Department of … WebJun 30, 2024 · “The top-line results of the randomized ZUMA-7 trial paint the picture of a potential paradigm shift in the treatment of large B-cell lymphoma,” Frederick L. Locke, MD, ZUMA-7 lead principal investigator and co-leader of the Immuno-Oncology Program at Moffitt Cancer Center in Tampa, Florida, said in a press release.
WebDec 13, 2024 · Frederick L. Locke, MD, of Moffitt Cancer Center in Tampa, Florida, is the lead study author of the phase 3 ZUMA-7 trial, which examined the use of axi-cel in second-line treatment of patients ... WebFrederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the …
WebResides in Glendale, AZ. Lived In Litchfield Park AZ, Buckeye AZ, Phoenix AZ, Peoria AZ. Related To Christine Locke, Kimberly Locke, George Locke, Frankie Locke, Catherine … WebDr. Locke went on to state that 6-month PFS rates were consistent across key covariates. A median PFS of 5.9 months (95% CI, 3.4–9.8) was reported and median OS is not reached at the median follow-up of 8.7 months (95% CI, 10.5–NR). Compared with the SCHOLAR-1 data, 6-month OS rate is higher in the ZUMA-1 trial: 55% versus 80%, respectively.
WebDec 11, 2024 · Jacobson CA, Locke FL, Ghobadi A, et al. Long-term (4- and 5-year) overall survival in ZUMA-1, the pivotal study of axicabtagene ciloleucel in patients with refractory large B-cell lymphoma.
WebDec 11, 2024 · Jacobson CA, Locke FL, Ghobadi A, et al. Long-term (4- and 5-year) overall survival in ZUMA-1, the pivotal study of axicabtagene ciloleucel in patients with refractory … high speed rolling shutterWebOct 28, 2024 · Dec 9, 2024. Tomorrow at @ASH22: Dr. Frederick L. Locke (@drfredlocke) of @MoffittNews presents on the association of metabolic tumor volume and clinical outcomes following axicabtagene ciloleucel versus standard-of-care therapy in ZUMA-7. @ASH_hematology Read more bit.ly/3UKWF7h. high speed rotary bufferWebMar 17, 2024 · Fred Locke is a Construction Management at John M Campbell based in Tulsa, Oklahoma. Previously, Fred was a Construction Management at PeakCM and also held positions at Edison Foard, Associated Construction, Heffner & Weber, Hylwa. Read More . Contact. Fred Locke's Phone Number and Email high speed rolling shutter doorsWebFeb 26, 2024 · Fred Locke, MD, Moffitt Cancer Center discusses the interim results of the ZUMA-I trial of Kte-C19, a CAR T-cell therapy. Frederick Locke, MD, Moffitt Cancer … how many days of school can you miss in azWebJun 1, 2024 · Methods: ZUMA-2 (NCT02601313) is enrolling pts with R/R MCL sequentially into 2 separate dose level cohorts (~40 pts each). After leukapheresis and manufacturing, pts will receive conditioning chemotherapy with fludarabine 30 mg/m 2 /d and cyclophosphamide 500 mg/m 2 /d × 3 d and then receive a single infusion of KTE-C19 … how many days of school are there in texasWebLocke, et al. Supplementary Appendix 3 ZUMA-7 Study Team Study Team Member Site Investigators Avivi, Irit, M.D. Tel Aviv Sourasky Medical Center, Tel Aviv, Israel high speed router for streamingWebFeb 25, 2024 · Fred Locke, MD, Moffit Cancer Center, discusses the interim results from the ZUMA-I trial of Kte-C19. how many days of school are there in michigan